Analysts at Leerink Partnrs lifted their FY2026 earnings estimates for Travere Therapeutics in a research report issued to ...

Investment analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of AstraZeneca in a note issued to ...

Schrodinger Inc (SDGR) stock saw a modest uptick, ending the day at $24.34 which represents a slight increase of $3.01 or 14.11% from the prior close of $21.33. The stock opened at $21.52 and touched ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Leerink said its prior rating had been based on FY24 being a "weaker" year as aligner demand normalized against a "tougher macro backdrop" and "uncertainty of how new launches would benefit earnings." ...

Beta Bionics (BBNX), a maker of insulin delivery devices, has disclosed terms for an upsized $113M initial public offering.

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

https://www.tipranks.com/news/the-fly/trulieve-cannabis-price-target-lowered-to-c19-from-c23-at-alliance-global-partners Leerink keeps an Outperform rating and a $60 ...

https://www.tipranks.com/news/the-fly/iteos-therapeutics-price-target-lowered-to-19-from-31-at-wells-fargo Leerink analyst Christopher Liu lowered the firm’s price ...